Value Sense
LBPH
Longboard Pharmaceuticals, Inc. (LBPH)
Last Price$60.00.0%
Market Cap$2,336.7M
LTM Quick ratio
15.7x
5Y avg
14.4x
Biotechnology industry median
4.3x
Stock quality & Intrinsic value
6/10
(0.8%) overvalued
LBPH
is (81.3%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Longboard Pharmaceuticals, Inc. Quick ratio

Annual
Quarterly
LTM
Industry median
Company stand-alone
LBPH
Healthcare
Crunching data... Almost there!
Dec'20Dec'21Dec'22Dec'23
Quick ratio
17.6x
19.6x
7.7x
5.0x
LBPH
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for LBPH and see if it's the right time to invest.
Dive in

Longboard Pharmaceuticals, Inc. (LBPH) Quick ratio comparison analysis

General

LTM Quick ratio

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

Longboard Pharmaceuticals, Inc. logo
Longboard Pharmaceuticals, Inc.LBPH
15.7x
N/A
(4.8%)
N/A
Median Peer Set
2.8x
14.8%
(19.3%)
7.5%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
29.7x
8.3%
10.4%
31.1%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
9.9x
N/A
(68.7%)
N/A
BioNTech SE logo
BioNTech SEBNTX
7.3x
(77.4%)
(89.7%)
24.4%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
4.8x
23.6%
25.7%
41.5%
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.BMRN
3.0x
18.0%
139.3%
15.0%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
2.6x
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
2.2x
11.7%
N/A
(4.9%)
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
1.6x
73.7%
467.1%
(35.9%)
Royalty Pharma plc logo
Royalty Pharma plcRPRX
1.4x
(3.8%)
(43.7%)
37.9%
argenx SE logo
argenx SEARGX
N/A
198.6%
(60.5%)
(24.1%)

LBPH key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.0
0.0%
0.0
0.0%
0.0
0.0%
0.0
0.0%
Cost of Goods Sold (COGS)0.00.00.00.0
Gross Profit
% margin
0.0
0.0%
(0.0)
0.0%
(0.0)
0.0%
(0.0)
0.0%
Operating Expenses14.427.844.856.8
Research & Development Expenses (R&D)4.619.834.643.8
Selling, General & Administrative Expenses (SG&A)9.88.110.213.0
Operating Income
% margin
(14.4)
0.0%
(27.8)
0.0%
(44.8)
0.0%
(56.8)
0.0%
Interest Income0.00.10.82.4
Interest Expense0.00.00.80.0
Pre-tax Income(14.4)(27.8)(43.9)(54.4)
Income Tax
% effective tax rate
(0.0)
0.1%
(0.1)
0.2%
(0.9)
1.9%
0.0
0.0%
Net Income
% margin
(14.4)
0.0%
(27.7)
0.0%
(43.1)
0.0%
(54.4)
0.0%
EPS(0.82)(1.62)(2.51)(2.39)
Diluted EPS(0.82)(1.62)(2.51)(2.39)
EBITDA
% margin
(14.4)
0.0%
(27.8)
0.0%
(44.8)
0.0%
(56.8)
0.0%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Longboard Pharmaceuticals, Inc.'s Quick ratio?

As of today, Microsoft Corp's last 12-month Quick ratio is 15.7x, based on the financial report for Sep 30, 2024 (Q3’2024). The average annual Quick ratio for Longboard Pharmaceuticals, Inc. have been 17.1x over the past three years, and 13.7x over the past five years.

2) Is Longboard Pharmaceuticals, Inc.'s Quick ratio Good?

As of today, Longboard Pharmaceuticals, Inc.'s Quick ratio is 15.7x, which is higher than industry median of 4.3x. It indicates that Longboard Pharmaceuticals, Inc.'s Quick ratio is Good.

3) How does Longboard Pharmaceuticals, Inc.'s Quick ratio compare to its peers?

As of today, Longboard Pharmaceuticals, Inc.'s Quick ratio is 15.7x, which is higher than peer median of 2.8x. The list of peers includes REGN, SMMT, BNTX, UTHR, BMRN, ALNY, VRTX, BGNE, RPRX, ARGX.